Search results for "Adjuvant"
showing 10 items of 733 documents
Place de l’imagerie dans l’évaluation de l’efficacité des traitements dans le cancer du sein
2010
Resume Cette revue decrit le role de differentes methodes d’imagerie pour evaluer la reponse au traitement dans le cancer du sein. Deux situations sont envisageables : celle de la chimiotherapie neoadjuvante du cancer du sein et celle des metastases. Beaucoup de donnees cliniques sont disponibles pour trois criteres : le volume de la tumeur, la captation du fluorodeoxyglucose mesuree en TEP et la perfusion de la tumeur evaluee soit par IRM dynamique, soit en TEP. La TEP au 2-18F fluoro-2-desoxy-D-glucose (FDG) permet la prediction de la reponse apres une ou deux cures de chimiotherapie. De nouvelles approches pourraient prochainement affiner le role de l’imagerie. Ainsi, la TEP a la thymidi…
German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breas…
2014
1009 Background: Intense dose-dense (idd) epirubicin (E), paclitaxel (T), cyclophosphamide (C) (idd-ETC) resulted in a superior disease-free (DFS) and overall survival (OS) compared to conventional...
The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathologic subtyp…
2013
1031 Background: According to observational studies, obesity is an unfavourable prognostic factor in breast cancer (BC), regardless of menopausal status and treatment received. Information collected in clinical trials should confirm this effect and serves to test its homogeneity by pathologic subtype. Methods: We retrospectively analysed 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, 9805, 2003–02, and BCIRG 001) evaluating adjuvant anthracyclines and taxanes. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differ…
Outcome Prediction in Node-Negative Breast Cancer Based on ASCO-Recommended Biomarkers uPA/PAI-1 Using the Final 10-Year Analysis of the Randomized M…
2009
Abstract Background: Based on interim analysis of Chemo N0, the first prospective multicenter randomized clinical trial using biomarkers uPA/PAI-1 for risk stratification and chemotherapy selection in N0 breast cancer, uPA/PAI-1 are now recommended for routine use by ASCO and AGO guidelines. Final 10-year follow-up of Chemo N0 has validated the clinically relevant long-term prognostic and predictive impact of uPA/PAI-1 in N0 breast cancer. To quantify the clinical utility of this impact, outcomes in subgroups defined by these biomarkers were compared to predictions of Adjuvant Online™, the leading validated tool based on established clinical factors. Methods: In Chemo N0, patients (n=647, 1…
Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice
2013
Epithelial ovarian cancer (EOC) is the sixth most common malignancy in women. Ovarian tumors consist of several clinical and pathological entities that share an anatomic site. The gold standard treatment, both in front-line and in adjuvant setting, is represented by carboplatin/paclitaxel combination. Conversely, the second-line treatment is not well defined. The response to platinum is the major prognostic factor for survival. In this review we discuss the current views on platinum-refractory/resistant patient treatment only, which includes patients progressing or relapsing within 6 months from the last platinum-based course. Concerning this subgroup, the activity of several conventional d…
In breast cancer, are treatments and survival the same whatever a patient's age? A population-based study over the period 1998-2009
2014
Aim The present study aimed to describe treatments, relative survival and prognostic factors in breast cancer patients according to age. Methods All women with primary invasive breast cancer, diagnosed from 1998 to 2009 in the department of Cote d'Or, were retrospectively selected. Variations in treatments administered according to age ( 74 years) and period were assessed using Cochran–Armitage trend tests and χ2-tests, respectively. Prognostic factors according to age were estimated using a generalized linear model with a Poisson error structure. Results Overall, 4305 women were included. The oldest women (aged >74 years) were more likely than the youngest women to have comorbidities, adva…
Chirurgische Radikalität und Indikation zur adjuvanten Therapie bei malignen Weichteiltumoren — Ergebnisse einer Registerstudie / The Extent of Radic…
2001
Ziel dieser Studie der Chirurgischen Arbeitsgemeinschaft Onkologie (CAO) der Deutschen Gesellschaft fur Chirurgie war die Erfassung eines aktuellen Status des chirurgisch-onkologischen Vorgehens bei malignen Weichteiltumoren des Erwachsenen. In 19 Monaten wurden die Daten von 292 Patienten aus 99 Kliniken prospektiv erfast. 39% wurden an Uni-Kliniken, 36% in Schwerpunkt- und 24% in Krankenhausern der Grundversorgung therapiert. An den Extremitaten konnte in 96% ein extremitatenerhaltender Eingriff durchgefuhrt werden. Die Haufigkeit einer RO-Resektion unterschied sich in den einzelnen Kliniken nicht signifikant, jedoch kamen lokal ausgedehntere Verfahren und additive Masnahmen an Uni-Klinik…
Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuva…
2021
167 Background: NIVO is the first adjuvant therapy to provide a statistically significant and clinically meaningful improvement in disease-free survival (DFS) versus PBO in resected EC/GEJC following neoadjuvant chemoradiotherapy as demonstrated by CheckMate 577. NIVO was well tolerated with an acceptable safety profile. This analysis provides additional information on the exploratory HRQoL endpoints in this clinical trial. Methods: The effect of NIVO versus PBO on HRQoL, including general and disease-related symptoms, functioning, disease burden, and overall QoL, was assessed using FACT-E and EQ-5D-3L patient-reported outcome (PRO) questionnaires administered at baseline (BL), every 4 wee…
Chemotherapy-induced cardiotoxicity: role of the conventional echocardiography and the tissue Doppler.
2011
Aim. The cardiotoxicity of anticancer drugs is an emerging problem and only an identification of the early signs of cardiotoxicity by conventional echocardiography and not (tissue Doppler imaging, TDI), will limit and contain the long-term cardiotoxicity effects. The aim of this study was to identify, through conventional echocardiography and TDI, parameters to use as early "signs" of cardiotoxicity. Methods. A prospective study was performed using patients with breast cancer (72 women, median age 57+/-12) treated with anticancer drugs (adjuvant chemotherapy). All patients underwent a careful cardiological evaluation before starting treatment (T0) and during follow-up at 3 months (T1), 6 mo…
Gene expression specificity of the mussel antifungal mytimycin (MytM)
2011
Abstract We previously reported the nucleotide sequences and diversity of mytimycin (MytM) from the Mediterranean mussel, Mytilus galloprovincialis. Using real-time PCR (q-PCR), we observed that the MytM gene was mainly expressed in circulating hemocytes and to a less extent in the mantle. In vivo challenge with bacteria or with the yeast, Candida albicans, did not increase the expression as measured by q-PCR in hemocytes. By contrast, injection of the filamentous fungus, Fusarium oxysporum, induced a sudden and strong increase of expression at 9h p.i. (stimulation index of 25.7 ± 2.1). Optimum stimulating dose was 104 spores of F. oxysporum per mussel. In the same samples, AMP mytilin and …